1
|
Gagneux-Brunon A, Detoc M, Bruel S, Tardy B, Rozaire O, Frappe P, Botelho-Nevers E. Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: a cross-sectional survey. J Hosp Infect 2020; 108:168-173. [PMID: 33259883 PMCID: PMC7699157 DOI: 10.1016/j.jhin.2020.11.020] [Citation(s) in RCA: 349] [Impact Index Per Article: 87.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2020] [Revised: 11/24/2020] [Accepted: 11/25/2020] [Indexed: 01/07/2023]
Abstract
Background Healthcare workers (HCWs) are at the frontline of the COVID-19 pandemic and identified as a priority target group for COVID-19 vaccines. We aimed to determine COVID-19 vaccine acceptance rate in HCWs in France. Methods We conducted an anonymous survey from 26th March to 2nd July 2020. The primary endpoint was the intention to get vaccinated against COVID-19 if a vaccine was available. Results Two-thousand and forty-seven HCWs answered the survey; women accounted for 74% of respondents. Among respondents, 1.554 (76.9%, 95% confidence interval 75.1–78.9) would accept a COVID-19 vaccine. Older age, male gender, fear about COVID-19, individual perceived risk and flu vaccination during previous season were associated with hypothetical COVID-19 vaccine acceptance. Nurses and assistant nurses were less prone to accept vaccination against COVID-19 than physicians. Vaccine hesitancy was associated with a decrease in COVID-19 vaccine acceptance. Flu vaccine rate was 57.3% during the previous season, and 54.6% of the respondents had the intention to get a flu vaccine during the next season. Conclusions Intention to get vaccinated against COVID-19 reached 75% in HCWs with discrepancies between occupational categories. COVID-19 pandemic had no positive effect on flu vaccine acceptance rate.
Collapse
Affiliation(s)
- A Gagneux-Brunon
- Department of Infectious and Tropical Diseases, University Hospital of Saint-Etienne, Saint-Etienne, France; Centre d'investigation Clinique 1408-INSERM, University Hospital of Saint-Etienne, Saint-Etienne, France; Groupe Immunité des Muqueuses et Agents Pathogènes EA3064, University Jean Monnet, Université de Lyon, Saint-Etienne, France; Institut PRESAGE, Chaire Prevention Vaccination et Contrôle de L'Infection, University Jean Monnet, Université de Lyon, Saint-Etienne, France.
| | - M Detoc
- Department of Infectious and Tropical Diseases, University Hospital of Saint-Etienne, Saint-Etienne, France; Centre d'investigation Clinique 1408-INSERM, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - S Bruel
- Department of General Medicine, Faculté de Médecine Jacques Lisfranc, University Jean Monnet, Université de Lyon, Saint-Etienne, France
| | - B Tardy
- Centre d'investigation Clinique 1408-INSERM, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - O Rozaire
- Union Régionale des Professionnels de Santé Pharmaciens, Auvergne Rhône Alpes, France
| | - P Frappe
- Centre d'investigation Clinique 1408-INSERM, University Hospital of Saint-Etienne, Saint-Etienne, France; Department of General Medicine, Faculté de Médecine Jacques Lisfranc, University Jean Monnet, Université de Lyon, Saint-Etienne, France
| | - E Botelho-Nevers
- Department of Infectious and Tropical Diseases, University Hospital of Saint-Etienne, Saint-Etienne, France; Centre d'investigation Clinique 1408-INSERM, University Hospital of Saint-Etienne, Saint-Etienne, France; Groupe Immunité des Muqueuses et Agents Pathogènes EA3064, University Jean Monnet, Université de Lyon, Saint-Etienne, France; Institut PRESAGE, Chaire Prevention Vaccination et Contrôle de L'Infection, University Jean Monnet, Université de Lyon, Saint-Etienne, France
| |
Collapse
|
2
|
Detoc M, Launay O, Dualé C, Mutter C, Le Huec JC, Lenzi N, Lucht F, Gagneux-Brunon A, Botelho-Nevers E. Barriers and motivations for participation in preventive vaccine clinical trials: Experience of 5 clinical research sites. Vaccine 2019; 37:6633-6639. [PMID: 31543417 DOI: 10.1016/j.vaccine.2019.09.048] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Revised: 09/10/2019] [Accepted: 09/11/2019] [Indexed: 01/09/2023]
Abstract
Recruitment in preventive vaccine trials (PVT) is challenging due to common barriers to clinical research and lack of vaccine confidence. Identifying determinants of participation can help to improve recruitment. A prospective survey was conducted in 5 French clinical investigational sites. People asked to participate in a PVT were given a questionnaire whether they decided to participate or not in the trial. A total of 341 people answered the survey: 210 accepting and 131 declining to participate in a PVT. Acceptors were significantly younger (38.5 vs 54.9 years old), more likely to be involved in early phase trials, had a higher level of education (p < 0.005) and a significantly better general opinion concerning vaccines (92.3% versus 72.3%, p < 0.005) compared with those who declined. Factors associated with acceptance or refusal were evaluated in 224 people in the 4 sites where both groups were included. In a multivariate analysis, three factors: older age, having heard about PVT through multiple sources and financial incentives were significantly associated with refusal to participate in the PVT. A generally favourable opinion of vaccines was associated with acceptance. The main motivation for participation was altruism (93.2%) whereas fear of side effects was at the forefront of the barriers (36.6%). Information given by the physician was a key point for decision-making in 70.2% of those who accepted. In brief, vaccine hesitancy may decrease recruitment in PVTs; reinforcing altruism and quality of information given are key points in acceptance of participation in PVT.
Collapse
Affiliation(s)
- M Detoc
- Clinical Trial Center, INSERM CIC 1408, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 - Medical School of Saint-Etienne, University of Lyon, France; Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France
| | - O Launay
- Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France; Université Paris Descartes, Sorbonne Paris Cité, France; Inserm, CIC 1417, Assistance Publique-Hôpitaux de Paris, CIC Cochin Pasteur, Hôpital Cochin Broca Hôtel-Dieu, Paris, France
| | - C Dualé
- Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France; Centre de Pharmacologie Clinique (INSERM CIC1405), CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - C Mutter
- Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France; CIC Inserm 1434, CHU de Strasbourg, Strasbourg, France
| | - J-C Le Huec
- Polyclinique Bordeaux Nord Aquitaine, Unité Rachis, Université Bordeaux Deterca Lab, 15 rue Boucher, 33000 Bordeaux, France
| | - N Lenzi
- Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France
| | - F Lucht
- Clinical Trial Center, INSERM CIC 1408, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 - Medical School of Saint-Etienne, University of Lyon, France; Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France
| | - A Gagneux-Brunon
- Clinical Trial Center, INSERM CIC 1408, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 - Medical School of Saint-Etienne, University of Lyon, France; Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France
| | - E Botelho-Nevers
- Clinical Trial Center, INSERM CIC 1408, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 - Medical School of Saint-Etienne, University of Lyon, France; Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France.
| |
Collapse
|
3
|
Ben Khalifa E, Detoc M, Lefebvre A, Huet J, Titoulet S, Legrand D, Cognasse F, Vallet P. Inflammation et écologie du stress en application au don de sang : expérience au sein de l’EFS Auvergne–Rhône-Alpes (Saint-Étienne). Transfus Clin Biol 2019. [DOI: 10.1016/j.tracli.2019.06.204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
4
|
Khalifa EB, Detoc M, Lefebvre A, Huet J, Titoulet S, Legrand D, Cognasse F, Vallet P. Analyse du discours des donneurs : expérience au sein de l’EFS Auvergne-Rhône-Alpes (St-Étienne). Transfus Clin Biol 2019. [DOI: 10.1016/j.tracli.2019.06.239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Detoc M, Touche C, Charles R, Lucht F, Gagneux-Brunon A, Botelho-Nevers E. Primary physicians' attitudes toward their patients receiving a proposal to participate in a vaccine trial. Hum Vaccin Immunother 2019; 15:2969-2979. [PMID: 31241393 DOI: 10.1080/21645515.2019.1625646] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
A trustworthy relationship between primary physicians (PPs) and their patients is crucial for vaccine acceptance. Little is known about attitudes of PPs toward participation of their patients in a preventive vaccine trial (PVT) proposed by investigation sites.A cross-sectional study was conducted in Auvergne-Rhône-Alpes region (France) including an anonymous questionnaire for general practitioners (GPs) and other specialists as well as face-to-face interviews. A scenario of a patient, with chronic medical conditions, invited to participate in a PVT and reporting this situation to his/her PP was drawn up. PPs' attitudes were assessed in quantitative approach by a 5-point Likert scale and in qualitative approach by semi-directed individual interviews.Among the 521 respondents to the questionnaire, 429 (82.3%) were GPs and 92 (17.7%) were other specialists. Only 7.5% (39/521) of respondents regularly practice clinical research. Confronted with the scenario, 312 respondents (59.8%) declared they would give their opinion spontaneously. Before giving their opinion, PPs would like more information about the trial (91.4%, n = 476). Whatever their attitude, 488 (93.7%) would be influenced by available safety data. Face-to-face interviews confirmed that PPs lack of knowledge about clinical research, and would like to obtain information from investigators, particularly about safety.PPs seem to be concerned by the decision of their patients to participate or not in a PVT but would like more information about the trial and clinical research before giving their opinion. Getting PPs to be more involved in the enrollment of patients in PVT may improve recruitment.
Collapse
Affiliation(s)
- Maelle Detoc
- Clinical trial center, INSERM CICEC 1408, University Hospital of Saint-Etienne, Saint-Etienne, France.,Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 - Medical School of Saint-Etienne, University of Lyon, Saint-Etienne, France
| | - Camille Touche
- General Practice Department, University of Lyon, Saint-Etienne, France
| | - Rodolphe Charles
- General Practice Department, University of Lyon, Saint-Etienne, France
| | - Frédéric Lucht
- Clinical trial center, INSERM CICEC 1408, University Hospital of Saint-Etienne, Saint-Etienne, France.,Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 - Medical School of Saint-Etienne, University of Lyon, Saint-Etienne, France
| | - Amandine Gagneux-Brunon
- Clinical trial center, INSERM CICEC 1408, University Hospital of Saint-Etienne, Saint-Etienne, France.,Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 - Medical School of Saint-Etienne, University of Lyon, Saint-Etienne, France
| | - Elisabeth Botelho-Nevers
- Clinical trial center, INSERM CICEC 1408, University Hospital of Saint-Etienne, Saint-Etienne, France.,Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 - Medical School of Saint-Etienne, University of Lyon, Saint-Etienne, France
| |
Collapse
|
6
|
Pouvaret A, Maillard N, Roblin X, Marotte H, Detoc M, Gagneux-brunon A, Botelho-nevers E. Vaccins chez l’immunodéprimé : point de vue des patients. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
7
|
Pouvaret A, Maillard N, Roblin X, Marotte H, Detoc M, Botelho-nevers E, Gagneux-Brunon A. Couverture vaccinale des patients immunodéprimés : des disparités selon les spécialités. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Hoyon M, Detoc M, Boyer B, Berthelot P, Verhoeven P, Botelho-Nevers E. Connaissances et croyances sur les infections associées aux soins chez les patients allant bénéficier d’une pose de prothèse articulaire. Med Mal Infect 2018. [DOI: 10.1016/j.medmal.2018.04.212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
9
|
Detoc M, Gagneux-Brunon A, Lucht F, Botelho-Nevers E. Barriers and motivations to volunteers' participation in preventive vaccine trials: a systematic review. Expert Rev Vaccines 2017; 16:467-477. [PMID: 28277098 DOI: 10.1080/14760584.2017.1297706] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
INTRODUCTION The recruitment of volunteers in preventive vaccine trials (PVT) is a challenge, since vaccine hesitancy and debates on vaccines are combined to usual difficulties of enrollment in clinical trials. Areas covered: Current knowledge of the reasons leading to the volunteers' participation or non-participation in PVT mainly focuses on data from preventive HIV vaccine trials. A systematic PubMed search was conducted using PRISMA guidelines to identify articles or reviews that reported barriers and motivations to participation in PVT regardless of the targeted disease or population. Expert commentary: In view of the barriers and motivations reviewed here, improvements in recruitment could be made through a better explanation of the prevented disease, of the expected individual and collective benefit and of all ethical protective principles associated to the trials. Use of decision aids as well as patient and public involvement may improve given information and may enhance comprehension of participants and their participation in PVT. Further prospective and interventional studies are needed to analyze if these leads may improve acceptation level in PVT.
Collapse
Affiliation(s)
- M Detoc
- a Clinical Trial Center , INSERM CIC 1408, University Hospital of Saint-Etienne , Saint-Etienne , France.,b Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 , Medical School of Saint-Etienne, University of Lyon , Saint-Etienne , France
| | - A Gagneux-Brunon
- a Clinical Trial Center , INSERM CIC 1408, University Hospital of Saint-Etienne , Saint-Etienne , France.,b Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 , Medical School of Saint-Etienne, University of Lyon , Saint-Etienne , France
| | - F Lucht
- a Clinical Trial Center , INSERM CIC 1408, University Hospital of Saint-Etienne , Saint-Etienne , France.,b Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 , Medical School of Saint-Etienne, University of Lyon , Saint-Etienne , France
| | - E Botelho-Nevers
- a Clinical Trial Center , INSERM CIC 1408, University Hospital of Saint-Etienne , Saint-Etienne , France.,b Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 , Medical School of Saint-Etienne, University of Lyon , Saint-Etienne , France
| |
Collapse
|
10
|
Tsilanizara A, Diop CM, Nimal B, Detoc M, Lunéville L, Chiron M, Huynh TD, Brésard I, Eid M, Klein JC, Roque B, Marimbeau P, Garzenne C, Parize JM, Vergne C. DARWIN: An Evolution Code System for a Large Range of Applications. J NUCL SCI TECHNOL 2014. [DOI: 10.1080/00223131.2000.10875009] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|